معرفی
Frederik Cleeren serves as an Assistant Professor in the Department of Pharmaceutical and Pharmacological Sciences within KU Leuven's Faculty of Pharmaceutical Sciences. He heads the Subdivision Miracle-FC and holds multiple leadership roles including membership in the Council of the Faculty of Pharmaceutical Sciences, Pharmaceutical Sciences Doctoral Committee, and Departmental Council. His research focuses on developing radiopharmaceuticals for cancer diagnosis and therapy with emphasis on pancreatic cancer, tuberculosis, and CXCR4-targeted agents.
His primary research areas include Radiopharmaceutical Research, Molecular Imaging, and Targeted Radionuclide Therapy, particularly utilizing terbium-161 and actinium-225 for alpha particle therapy. Current projects involve developing 18F- and 213Bi-radiopharmaceuticals for tuberculosis, therapeutic agents for pancreatic cancer, and FAP-targeted radiopharmaceuticals. His work bridges radiochemistry, preclinical validation, and clinical translation.
Analysis of his 15 most recent publications reveals strong focus on CXCR4-targeted imaging (4 articles), terbium-based theranostics (3 articles), and comparative clinical imaging studies (3 articles). Key trends include development of novel chelators for alpha emitters, mitochondria-targeting strategies to enhance radiation dose, and clinical validation of new PET tracers against established standards.
Dr. Cleeren actively mentors students including M.A. Spahn (PhD candidate), J.F. Santos, H. Leupe, and M. Cuypers. His research is supported by multiple grants including a 2025 gamma spectrometer project and pancreatic cancer theranostics initiatives running through 2028.
His laboratory focuses on Radiopharmaceutical Research within the ON2 Herestraat facility, specializing in preclinical evaluation of diagnostic and therapeutic radiotracers. Current infrastructure includes development of automated production systems for radiopharmaceuticals and advanced imaging platforms for molecular validation.
